COVID-19 Collection

Journal article

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial

Abstract:: Background: Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV.

Methods: In this single-arm open-label vaccination substudy within the protocol of the larger phase 2/3 trial COV002...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Frater, J., Ewer, K., Ogbe, A., Pace, M., Adele, S., Adland, E., Aley, P., Ali, M., Ansari, M., Bittaye, M., Brown, A., Brown, H., Cappuccini, F., Dejnirattisai, W., Dold, C., Moreira Folegatti, P., Fowler, J., Jenkin, D., Makinson, R., … Lambe, T. (2021). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial. Lancet HIV, 8(8), E474–E485.

MLA Style

Frater, J, et al. “Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in HIV Infection: a Single-Arm Sub-Study of a Phase 2/3 Clinical Trial.” Lancet HIV, vol. 8, no. 8, 2021, pp. E474–E485.

Chicago Style

Frater, J, K Ewer, A Ogbe, et al. 2021. “Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in HIV Infection: a Single-Arm Sub-Study of a Phase 2/3 Clinical Trial.” Lancet HIV 8 (8): E474–E485.
Print

Access Document

Files:: Frater_et_al_2021_Safety_and_immunogenicity.pdf

(Preview, Version of record, pdf, 896.3KB, Terms of use)

Publisher copy:: 10.1016/S2352-3018(21)00103-X

Authors

+ Frater, J More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Biomedical Services
Role:: Author

+ Ewer, K More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Biomedical Services
Role:: Author
ORCID:: 0000-0001-9827-9836

+ Ogbe, A More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Role:: Author
ORCID:: 0000-0001-7774-7215

+ Pace, M More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Role:: Author

+ Adele, S More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Role:: Author
ORCID:: 0000-0001-9934-9023

More authors...

Contributors

+ Oxford COVID Vaccine Trial Group

Role:: Contributor

Publisher:: Elsevier
Journal:: Lancet HIV More from this journal
Volume:: 8
Issue:: 8
Pages:: E474-E485
Publication date:: 2021-06-18
Acceptance date:: 2021-05-14
DOI:: 10.1016/S2352-3018(21)00103-X
ISSN:: 2405-4704

Language:: English
Keywords:: FFR
Pubs id:: 1182442
Local pid:: pubs:1182442
Deposit date:: 2021-06-17
ARK identifier:: ark:/29072/ora_fc7e0b901569445286ecda371361e515

Terms of use

Copyright holder:: Frater et al.
Copyright date:: 2021
Rights statement:: © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP